Checkpoint Therapeutics
Presence
Fortress Biotech is a company listed under the stock ticker FBIO (US).
Fortress Biotech has 4 subsidiaries including Avenue Therapeutics, Checkpoint Therapeutics and Journey Medical Corp.
They are in:
- Biotechnology80%
- Pharmaceuticals20%
Executives
View the org chart displaying its 8 main executives
Most searched biographies at Checkpoint Therapeutics
- James Oliviero, Presidentt, Chief Executive Officer and Director
- Christian Bechon, Director
- Barry Salzman, Director
Popular executive movements at Checkpoint Therapeutics
- Amit Sharma has joined the company as Director (posted on March 19 2024).
Create your alert
to follow the executive moves at Checkpoint Therapeutics.
Biotechnology
Fortress Biotech has 2,279 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
Popular contacts in Biotechnology
News
Press releases by Checkpoint Therapeutics
- Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
- Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
- Press Releases
- Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
- Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
- U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
- Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
- Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
- Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
- View more press releases Close
Social media about Checkpoint Therapeutics
- Checkpoint Therapeutics on Wikipedia, Google News & Yahoo Finance
- Checkpoint Therapeutics on LinkedIn, Twitter & YouTube
